Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.
Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.
Athithi Verma July 27, 2026
Susvimo won a CHMP recommendation as Europe’s first continuous-delivery wet AMD treatment, replacing monthly eye injections with two implant refills a year.
ADCs Graduated From Salvage to First Line, Twice in a Week
ADCs Graduated From Salvage to First Line, Twice in a Week
Europe Backs the Cholesterol Class That Failed Four Times
Europe Backs the Cholesterol Class That Failed Four Times
The Cheapest Drug in Retina Just Became a Branded Product
The Cheapest Drug in Retina Just Became a Branded Product
China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.
China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.
OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice
OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice

Editor’s Pick

One Trial Miss Cut AstraZeneca's Cushion Above $80bn to $800m

One Trial Miss Cut AstraZenecaโ€™s Cushion Above $80bn to $800m

White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift

White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift

Novo Nordisk Clears Court Hurdle in $10B Metsera Takeover as FTC Scrutiny Mounts

Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe

NeuroPulse


NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks

NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks

NeuroPulse Wk 29 First Brain Link Shares Movement Between Two People

NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People

OrphanPulse


OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice

OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice

OrphanPulse Wk 29 Ionis Takes SMA-Proven Antisense Into Dravet Syndrome

OrphanPulse Wk 29: Ionis Takes SMA-Proven Antisense Into Dravet Syndrome

DealPulse Signal


DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 29 The Biggest Deal of the Week Was a Bare Line

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

DealPulse Report


DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 29 The Biggest Deal of the Week Was a Bare Line

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.

Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.

Athithi Verma July 27, 2026
ADCs Graduated From Salvage to First Line, Twice in a Week

ADCs Graduated From Salvage to First Line, Twice in a Week

Athithi Verma July 27, 2026
Europe Backs the Cholesterol Class That Failed Four Times

Europe Backs the Cholesterol Class That Failed Four Times

Athithi Verma July 27, 2026
The Cheapest Drug in Retina Just Became a Branded Product

The Cheapest Drug in Retina Just Became a Branded Product

Athithi Verma July 27, 2026
China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.

China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.

Athithi Verma July 27, 2026
Agilent Has Built an Annuity on Merckโ€™s Clinical Programme, One Indication at a Time

Agilent Has Built an Annuity on Merckโ€™s Clinical Programme, One Indication at a Time

Athithi Verma July 23, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress